Neurodivergent traits in childhood double the risk of chronic disabling fatigue by age 18, with inflammation playing a significant mediating role. This highlights the importance of addressing inflammatory markers in managing the health of neurodivergent individuals.
Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial
SAN DIEGO — For years, Merck’s drug Keytruda has dominated cancer immunotherapy, racking up dozens of approvals, extending the lives of patients, and bringing in
September 8, 2024